Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Summary

This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.

Timeline

Start

2022-05-16

Primary completion

2022-09-07

Completion

2022-09-07

Drugs

Indications